Epic Sciences, Inc. and its research partners today report the use of the company’s new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of...
Read More »
The therapeutic landscape of lung cancer has expanded significantly over the past decade. Advancements in molecularly targeted therapies, strategies to discover and treat resistance mutations, and development of personalized cancer treatments in the context of tumor heterogeneity and dynamic tumor ...
Read More »
Epic Sciences announced findings demonstrating a circulating tumor cell (CTC) biomarker can identify patients with metastatic castrate resistant prostate cancer (mCRPC) who are more likely to respond to treatment with a PARP inhibitor in combination with androgen receptor signaling inhibitors ...
Read More »
Research and Markets has announced the “Circulating Tumor Cell, Cell Free DNA, Exosome and Vesicle Cancer Diagnostic Markets 2016-2020” report. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company ...
Read More »
Exosome RNA Exosome RNA Research & Industry News
